PIK3CA and neoplasm: In in vivo tumor growth studies, tumors carrying shRNAs that target NRAS alone, or combinations of BRAF and CRAF, or BRAF and PIK3CA, showed a significant delay in tumor growth (Figure 6E, 6H and 7D) compared to the corresponding sucrose controls.